Osteoporoza se definiše kao sistemski skeletni poremećaj sa smanjenom koštanom masom i mikroarhitekturalnim oštećenjem koštanog tkiva. Faktori rizika su pojave koje znatno menjaju očekivani apsolutni rizik, odnosno verovatnoću pojave bolesti u odredjenoj populaciji. Starenje i pušenje su najčešće navodjeni faktori rizika za razvoj osteoporoze. Cilj našeg rada bio je da utvrdi najčešće prisutne faktore rizika za nastanak osteoporoze. U našem istraživačkom radu je obradjeno ukupno 88 bolesnika koji su podeljeni u dve grupe prema broju popušenih cigareta i dužini pušačkog staža. Rezultati su pokazali da faktori rizika: loše životne navike (pušenje i uzimanje kafe), su značajno zastupljeni kod pacijenata obolelih od osteoporoze. Kako bi smo blagovremeno sproveli lečenje, zaključili smo na osnovu dobijenih rezultata, da je potrebno aktivno tragati za faktorima rizika odgovornim za nastanak osteoporoze.

Metformin is an anti-hyperglycemic agent used for the treatment of type 2 diabetes mellitus. Biguanides lower blood glucose levels primarily by decreasing the amount of glucose produced by the liver. Metformin also helps to lower blood glucose levels by making muscle tissue more sensitive to insulin so glucose can be absorbe. The purpose of the study was to establish the effect of metformin on insulin secretion in obese patients with newly diagnosed diabetes mellitus type 2. We included 40 patients with Type-2 Diabetes Mellitus, who were treated on Department for Internal Disease in Hospital King Milutin Laplje Selo. Patients included in the study were newly diagnosed with diabetes mellitus type 2, glycemia < 12 mmol/L, and hed the Body Mass Index >30 kg/m2. They were treated with metformin, 1000 mg/day. Insulin sensitivity was determined by HOMA IR, insulin secretion by HOMA, lipid status by spectrophotometry. After six months of treatment blood biochemistry tested again. BMI was also established. Metformin significantly lowered BMI (BMI before therapy 31.02 kg/m2, after treatment 28.7 kg/m2) (both p<0,001 vs baseline) waist circumference mean value 98±0.55 cm-93,12 cm. (p<0,001) During the therapy the glycaemia decreased from 11.7 mmol - 6,78 mmol/l, insulinemia mean value 20.141 mlU/l -13.691, HOMA IR elevated in all patients. Among the cholesterol fractions, most significant results were obtained in LDL cholesterol. Mean LDL cholesterol levels 4.51± 2.02 mmol/L. Mean cholesterol level 6.98±2.31 mmol/L. HDL levels -1.32 mmol/L. Serum triglycerides was (mean) 2.63±1.32mmol/L. After six months therapy Metformin produces beneficial changes in lipid states. Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity. Metformin produces beneficial changes in glycemia control, and moderated in weight, lipids and insulinemia. 

The metabolic syndrome is characterized by a group of metabolic risk factors causing type 2 diabetes (DM2) and cardiovascular diseases. At the heart of this pathogenic disorder is insulin resistance. The metabolic syndrome is often accompanied by diseases of the gallbladder (chronic inflammations and calculosis). The goal of our study was to observe the changes made on the gallbladder with patients diagnosed with the metabolic syndrome, specifically the presence of calculosis and cholecystitis. The study involved 130 patients with the metabolic syndrome and 40 healthy subjects, all of which were subjected to abdominal ultrasonography. Gallbladder calculosis was found in 36,92% subjects of the study group and 12,50% subjects of the control group, resulting in a statistically considerable difference (p<0,001). The results of our study indicate a significant presence of biliary calculosis as one of the manifestations of the metabolic syndrome on the biliary system.